Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis

Zab Mosenifar, MD

March 28, 2023

Anti-topoisomerase (Scl-70) antibodies are highly specific for SSc and have been associated with diffuse skin involvement and interstitial lung fibrosis. Patients with SSc and anti-topoisomerase (Scl-70) antibodies, may be at greater risk of developing ILD and disease progression. In contrast, patients with SSc and anti-centromere antibodies rarely develop SSc-ILD.

Other risk factors for progression in SSc-ILD include presence of diffuse disease, extent of parenchymal disease on HRCT of > 20% and FVC of < 70%.

Learn more about CTD-ILD.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Zab Mosenifar. Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis - Medscape - Mar 28, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Scleroderma Systemic Sclerosis ILD Presentation and Diagnosis

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Zab Mosenifar, MD

Comments

Email This

Feedback